Eris Lifesciences Limited
Simbolis: ERIS.NS
NSE
873.35
INRRinkos kaina šiandien
30.7423
P/E santykis
1.6041
PEG koeficientas
118.82B
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Eris Lifesciences Limited (ERIS-NS) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 5613.44 | 892.4 | 1772.4 | 522.7 | |||||||||||
balance-sheet.row.short-term-investments | 6124.75 | 332.2 | 1264.5 | 154 | |||||||||||
balance-sheet.row.net-receivables | 6515.97 | 2966.9 | 2260.9 | 2280.6 | |||||||||||
balance-sheet.row.inventory | 2705.24 | 1314.3 | 1179.1 | 944.7 | |||||||||||
balance-sheet.row.other-current-assets | 5222.75 | 2473.5 | 1060.8 | 922.5 | |||||||||||
balance-sheet.row.total-current-assets | 20057.4 | 7647.2 | 6273.3 | 4670.5 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 7998.42 | 3773.8 | 1918.6 | 778.8 | |||||||||||
balance-sheet.row.goodwill | 6636.98 | 3318.5 | 934.7 | 934.7 | |||||||||||
balance-sheet.row.intangible-assets | 37042.03 | 18806 | 6596 | 6840.8 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 43679.01 | 22124.5 | 7530.7 | 7775.5 | |||||||||||
balance-sheet.row.long-term-investments | 16.43 | 68.8 | 4208.4 | 2859.2 | |||||||||||
balance-sheet.row.tax-assets | 5690.48 | 2739.4 | 2431.3 | 2006.3 | |||||||||||
balance-sheet.row.other-non-current-assets | -2016.58 | 319.6 | 359 | 257.6 | |||||||||||
balance-sheet.row.total-non-current-assets | 55367.76 | 29026.1 | 16448.1 | 13677.3 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 75425.16 | 36673.3 | 22721.4 | 18347.8 | |||||||||||
balance-sheet.row.account-payables | 2752.94 | 1247.7 | 1177.7 | 1026.2 | |||||||||||
balance-sheet.row.short-term-debt | 3903.21 | 1932.9 | 40.1 | 23.3 | |||||||||||
balance-sheet.row.tax-payables | 176.96 | 39 | 70 | 77.5 | |||||||||||
balance-sheet.row.long-term-debt-total | 13158.94 | 6834.2 | 803.9 | 44.5 | |||||||||||
Deferred Revenue Non Current | 623.49 | 87.4 | 56.9 | 61.1 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 5109.42 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 438.6 | 217.2 | 152.4 | 132.5 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 19538.95 | 10034.2 | 1642.9 | 914.3 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 903 | 466.9 | 394 | 67.7 | |||||||||||
balance-sheet.row.total-liab | 28942.66 | 14466.5 | 3639.4 | 2583.6 | |||||||||||
balance-sheet.row.preferred-stock | 21930.12 | 21930.1 | 19062.4 | 15722.7 | |||||||||||
balance-sheet.row.common-stock | 272.01 | 136 | 135.9 | 135.8 | |||||||||||
balance-sheet.row.retained-earnings | 21559.3 | 21559.3 | 18736.5 | 15503.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 70084.98 | 29.8 | 20.7 | 41.5 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | -21288.35 | -21695.3 | -18872.5 | -15638.9 | |||||||||||
balance-sheet.row.total-stockholders-equity | 92558.06 | 21959.9 | 19083.1 | 15764.2 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 121907.66 | 36673.3 | 22721.4 | 18347.8 | |||||||||||
balance-sheet.row.minority-interest | 406.94 | 246.9 | -1.1 | 0 | |||||||||||
balance-sheet.row.total-equity | 92965 | 22206.8 | 19082 | 15764.2 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 121907.66 | - | - | - | |||||||||||
Total Investments | 5883.66 | 143.5 | 4208.4 | 2436.4 | |||||||||||
balance-sheet.row.total-debt | 17062.15 | 8767.1 | 844.1 | 67.8 | |||||||||||
balance-sheet.row.net-debt | 17573.46 | 8206.9 | 336.1 | -300.9 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 3864.39 | 4046.4 | 4422 | 3945 | |||||||||||
cash-flows.row.depreciation-and-amortization | 1638.34 | 1170.9 | 647 | 429.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | -809.7 | -976.6 | -670.9 | |||||||||||
cash-flows.row.stock-based-compensation | 31.21 | 31.2 | 13.6 | 11.2 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | -1755.4 | -299 | 53.3 | |||||||||||
cash-flows.row.account-receivables | 0 | -1171.4 | -204.8 | 159 | |||||||||||
cash-flows.row.inventory | 0 | 47.4 | -234.4 | -249.9 | |||||||||||
cash-flows.row.account-payables | 0 | -105 | 151.6 | 25.7 | |||||||||||
cash-flows.row.other-working-capital | 0 | -526.5 | -11.3 | 118.6 | |||||||||||
cash-flows.row.other-non-cash-items | -3895.6 | 233.9 | -24.4 | -14.7 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 2605.29 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -8414.2 | -1210.3 | -257.6 | |||||||||||
cash-flows.row.acquisitions-net | 0 | -6554.9 | -103 | -2.8 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -300 | -2677.7 | -3733.9 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 5204.4 | 795.9 | 774.2 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 243.7 | -1 | -13.4 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -9821 | -3196.1 | -3233.6 | |||||||||||
cash-flows.row.debt-repayment | 0 | -3500 | -450 | -0.1 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 22.8 | 67.5 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 3477.2 | -450 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | -999.1 | -816.2 | -746.8 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 7879.4 | 1201.8 | -77.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 6880.3 | -447 | -824 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 74.9 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 2605.29 | 51.5 | 139.6 | -303.9 | |||||||||||
cash-flows.row.cash-at-end-of-period | 6306.92 | 560.2 | 508.7 | 369.1 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 3701.63 | 508.7 | 369.1 | 673.1 | |||||||||||
cash-flows.row.operating-cash-flow | 2605.29 | 2917.4 | 3782.6 | 3753.6 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -8414.2 | -1210.3 | -257.6 | |||||||||||
cash-flows.row.free-cash-flow | 2605.29 | -5496.8 | 2572.3 | 3496 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 18406.22 | 16618.2 | 13261.7 | 11926.4 | |||||||||||
income-statement-row.row.cost-of-revenue | 3346.18 | 3523.5 | 2608.1 | 2418.7 | |||||||||||
income-statement-row.row.gross-profit | 15060.04 | 13094.7 | 10653.6 | 9507.8 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 61 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 1189.54 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 63.85 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 96.71 | 111.5 | 10.4 | 4.5 | |||||||||||
income-statement-row.row.operating-expenses | 10245.46 | 8898.1 | 6403 | 5620 | |||||||||||
income-statement-row.row.cost-and-expenses | 13591.64 | 12421.6 | 9011.1 | 8038.7 | |||||||||||
income-statement-row.row.interest-income | 402.19 | 23 | 61 | 22.9 | |||||||||||
income-statement-row.row.interest-expense | 606.36 | 261.7 | 41.5 | 18 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 63.85 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -596.47 | -170.2 | 176.9 | 68.9 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 96.71 | 111.5 | 10.4 | 4.5 | |||||||||||
income-statement-row.row.total-operating-expenses | -596.47 | -170.2 | 176.9 | 68.9 | |||||||||||
income-statement-row.row.interest-expense | 606.36 | 261.7 | 41.5 | 18 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 1638.34 | 1170.9 | 647 | 429.9 | |||||||||||
income-statement-row.row.ebitda-caps | 6549.63 | - | - | - | |||||||||||
income-statement-row.row.operating-income | 4901.4 | 4216.6 | 4245 | 3876.1 | |||||||||||
income-statement-row.row.income-before-tax | 4304.93 | 4046.4 | 4422 | 3945 | |||||||||||
income-statement-row.row.income-tax-expense | 515.94 | 304.8 | 364.1 | 393.6 | |||||||||||
income-statement-row.row.net-income | 3864.39 | 3821.6 | 4061.1 | 3551.3 |
Dažnai užduodami klausimai
Kas yra Eris Lifesciences Limited (ERIS.NS) bendras turtas?
Eris Lifesciences Limited (ERIS.NS) bendras turtas yra 36673280000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 9840010000.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.818.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 19.153.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.210.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.266.
Kas yra Eris Lifesciences Limited (ERIS.NS) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 3821580000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 8767110000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 8898080000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra -1906240000.000.